12:00 AM
Apr 01, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

NAV4694: Phase IIb started

Navidea began the open-label, U.S. Phase IIb NAV4-04 trial to evaluate 3 injections of NAV4694 over 36 months in about 50 patients with MCI. Navidea has exclusive, worldwide rights to the product...

Read the full 137 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >